Year: 2026 | Month: July | Volume: 16 | Issue: 7 | Pages: 145-154
DOI: https://doi.org/10.52403/ijhsr.20260715
Association of Serum Uric Acid Levels with Disease Severity and Short-Term Outcomes in Patients with Ischemic Heart Disease: A Prospective Observational Study
Anup Kumar Budhia1, Kalikinkar Chand2, Sandeep Kumar Prusty3, Biplabi Biswa Keshari Mohanty4, Sanjay Kumar Jangid5, Bijayalaxmi Parija6, Laxmikanta Dash7
1Associate Professor, Department of General Medicine, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India.
2Assistant Professor, Department of General Medicine, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India.
3Assistant Professor, Department of General Medicine, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India.
4Resident, Department of General Medicine, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India.
5Professor & HOD, Department of General Medicine, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India.
6Professor, Department of General Medicine, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India.
7Professor, Department of General Medicine, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India.
Corresponding Author: Dr. Biplabi Biswa Keshari Mohanty
ABSTRACT
Background: Serum uric acid (SUA) has emerged as a potential marker of cardiovascular risk and adverse outcomes in patients with ischaemic heart disease (IHD). However, its association with clinical severity, cardiac dysfunction, and short-term prognosis remains incompletely understood in hospitalized patients.
Objective: To evaluate the association of serum uric acid levels with disease severity, cardiac biomarkers, cardiac function, and short-term clinical outcomes among patients with ischaemic heart disease.
Methods: This prospective observational study was conducted among 80 adults diagnosed with angina, ST-segment elevation myocardial infarction (STEMI), or non-ST-segment elevation myocardial infarction (NSTEMI). Patients were stratified into three SUA categories: 4.0–5.5 mg/dL, 5.6–7.0 mg/dL, and >7.0 mg/dL. Clinical severity was assessed using Killip class, New York Heart Association (NYHA) functional class, and Global Registry of Acute Coronary Events (GRACE) risk score. Cardiac biomarkers, electrocardiographic findings, echocardiographic parameters, and short-term outcomes were compared across SUA categories.
Results: The majority of participants were aged ≥61 years (52.6%), and 72.5% were male. Higher SUA levels were significantly associated with greater clinical severity, including higher Killip class, worse NYHA functional class, and elevated GRACE risk scores throughout hospitalization (all p<0.001). Cardiac biomarkers, including troponin-T, troponin-I, and CK-MB, increased progressively with rising SUA levels (all p<0.001). Patients with SUA >7.0 mg/dL demonstrated more severe electrocardiographic abnormalities, greater left ventricular dysfunction, and significantly lower left ventricular ejection fraction values (all p<0.001).
Conclusion: Elevated serum uric acid levels are strongly associated with increased disease severity, myocardial injury, impaired cardiac function, and adverse short-term outcomes in patients with ischaemic heart disease.
Key words: Serum uric acid; Ischaemic heart disease; Acute coronary syndrome; Prognosis; Left ventricular dysfunction.